AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JUN 20 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Cancer and myeloma patients administered granulocyte-macrophage colony-stimulating factor (GM-CSF) for immune stimulation may produce GM-CSF-specific antibodies but not enough to neutralize its effects, according to a report in Clinical Immunology.
"We have assessed the immunogenicity profile of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with either colorectal carcinoma (CRC) at different stages of disease or with multiple myeloma who were given recombinant human GM-CSF (Escherichia coli-derived) combination therapy," reported G. Ullenhag and colleagues in Sweden.
The researchers administered high doses of GM-CSF (425-500 (micro)g/day for 10 days) to patients with advanced CRC, along with a colon cancer-reactive antibody. Other CRC patients and those with myeloma got low doses (75-80 (micro)g/day for four days) of GM-CSF adjuvant with appropriate tumor antigens.
Only 16% of low-dose patients developed GM-CSF-specific antibodies, compared with 55% of high-dose patients, and none developed neutralizing antibodies, said Ullenhag and coworkers.
Eighty percent of patients also developed antibodies to E. coli proteins that had contaminated the GM-CSF ("Incidence of GM-CSF antibodies in cancer patients ...
Source: HighBeam Research, Low Doses Of GM-CSF Not Enough To Stimulate Neutralizing...